Varsavsky's three companies—Inception (clinics), Overture (automation), and Gamito (therapeutics)—cater to different investor types. Investors in the predictable clinic business were unwilling to fund the higher-risk, longer-timeline R&D for automation and new drugs, forcing a multi-company structure.
Martin Varsavsky argues the FDA's core mandate, stemming from a century ago to prevent poisonings, is misaligned with modern medicine. It prioritizes avoiding any potential harm from a new treatment over the potential to save lives, especially for patients with grim alternatives.
Current incubators force underdeveloped lungs to breathe air. Varsavsky describes a 'liquid incubator' (like Vitara's) that uses artificial amniotic fluid and an umbilical cord, mimicking the womb. He predicts this far gentler alternative will make today's standard of care seem inhumane by comparison.
Varsavsky avoids in vitro gametogenesis (IVG) not for ethical reasons, but practical ones. Proving that an artificially created egg is safe requires proving it won't cause consequences later in the resulting human's life. This implies impossibly long clinical trials, making it a regulatory nightmare for a company.
Menopause causes systemic issues like osteoporosis and brain fog because a woman's ovaries age much faster than her body. Gamito's research aims to delay menopause, treating it as a longevity problem by preventing an "80-year-old ovary" from signaling aging to an otherwise healthy 45-year-old body.
Learning from Elon Musk's "over-robotization" at Tesla, Varsavsky's Overture focuses on automating the most difficult, skill-based steps in the IVF lab, like sperm injection (ICSI). They avoid automating simple tasks like moving a vial, which a human can do easily, ensuring a more practical and effective approach.
While automation helps reduce the cost of the embryology lab portion of IVF, its most significant impact is enabling clinics in smaller markets. An automated lab lowers the high upfront capital and specialized staffing needs, making IVF viable in areas that previously couldn't support a full-scale clinic.
To address the ethical dilemma of discarding excess embryos, some IVF clinics offer a "Christian IVF" option. Instead of fertilizing a batch of eggs, only one is fertilized and implanted per cycle. This avoids creating "leftover" embryos, making the process compatible with certain religious beliefs about the sanctity of life.
Varsavsky avoids polygenic screening (testing embryos for complex traits like IQ) because it's too speculative. He believes the probabilistic nature of the results and complex concepts like 'gene penetrance' are too difficult for the average patient to understand, making it an impractical, niche product for now.